Beta blocker for patients with pulmonary arterial hypertension: A single center experience.
暂无分享,去创建一个
F. Gaita | F. D’Ascenzo | C. Moretti | P. Omede' | E. Fusaro | W. Grosso Marra | S. Marra | F. Giordana | W. G. Marra | I. Meynet | M. Cannillo | U. Annone | Davide Salera | D. Libertucci | S. Chen | Sl Chen
[1] P. Ho,et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. , 2014, JAMA internal medicine.
[2] J. DiNicolantonio,et al. Choosing the best first line oral drug agent in patients with pulmonary hypertension: evidence from a network meta-analysis. , 2013, International journal of cardiology.
[3] Zhi-Hong Liu,et al. Echocardiographic Parameters in Patients with Pulmonary Arterial Hypertension: Correlations with Right Ventricular Ejection Fraction Derived from Cardiac Magnetic Resonance and Hemodynamics , 2013, PloS one.
[4] F. Gaita,et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. , 2013, European heart journal.
[5] D. Stewart,et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. , 2012, The American journal of cardiology.
[6] Daniel F. Freitag,et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012, The Lancet.
[7] W. Paulus,et al. Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension , 2012, Circulation. Heart failure.
[8] M. Ugander,et al. Enlarged right-sided dimensions and fibrosis of the right ventricular insertion point on cardiovascular magnetic resonance imaging is seen early in patients with pulmonary arterial hypertension associated with connective tissue disease , 2011, Scandinavian journal of rheumatology.
[9] N. Voelkel,et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. , 2010, American journal of respiratory and critical care medicine.
[10] E. K. Weir,et al. Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental Therapies , 2010, Circulation.
[11] W. Paulus,et al. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart , 2010, European Respiratory Review.
[12] M. Gatzoulis,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[13] A. Branzi,et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.
[14] S. Rich,et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.
[15] Martin J. Lohse,et al. What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure? , 2003, Circulation research.
[16] R. Lefkowitz,et al. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.
[17] M. Humbert,et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.